BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15095852)

  • 1. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
    Escher JC;
    Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
    Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
    Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
    McKeage K; Goa KL
    Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide for induction of remission in Crohn's disease.
    Otley A; Steinhart AH
    Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
    Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
    Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
    Florin TH; Graffner H; Nilsson LG; Persson T
    Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide in the treatment of Crohn's disease: a meta-analysis.
    Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group.
    Bar-Meir S; Chowers Y; Lavy A; Abramovitch D; Sternberg A; Leichtmann G; Reshef R; Odes S; Moshkovitz M; Bruck R; Eliakim R; Maoz E; Mittmann U
    Gastroenterology; 1998 Oct; 115(4):835-40. PubMed ID: 9753485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group.
    Ewe K; Böttger T; Buhr HJ; Ecker KW; Otto HF
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):277-82. PubMed ID: 10333200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
    Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
    Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
    Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide.
    Weigand K; Wagner-Thiessen E; Stolte M
    Z Gastroenterol; 2004 Oct; 42(10):1179-81. PubMed ID: 15508059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.
    Cohen SA; Aloi M; Arumugam R; Baker R; Bax K; Kierkuś J; Koletzko S; Lionetti P; Persson T; Eklund S
    Curr Med Res Opin; 2017 Jul; 33(7):1261-1268. PubMed ID: 28420280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.